Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Fortress Biotech, Inc. (FBIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.7900-0.0400 (-1.41%)
At close: 04:00PM EST
2.8000 +0.01 (+0.36%)
After hours: 05:33PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.8300
Open2.9100
Bid2.7600 x 1300
Ask2.9200 x 3000
Day's Range2.7800 - 2.9100
52 Week Range2.3600 - 6.1000
Volume476,459
Avg. Volume587,326
Market Cap277.966M
Beta (5Y Monthly)2.28
PE Ratio (TTM)N/A
EPS (TTM)-0.4760
Earnings DateNov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for FBIO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Fortress Biotech, Inc.
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total sales are generated in the United States.
    Rating
    Fair Value
    Economic Moat
    17 days agoMorningstar
View more
  • GlobeNewswire

    Journey Medical Corporation Introduces Expanded Board of Directors

    SCOTTSDALE, Ariz., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), expanded the company’s board of directors as part of its recent initial public offering to include four new independent directors: Jeffrey Paley, M.D., Justin Smith, Miranda Toledano and Neil Herskowitz. Lindsay Rosenwald, M.D., Executive Chairman, and Claude Maraoui, President and Chief Executive Officer, re

  • GlobeNewswire

    Avenue Therapeutics Announces Exercise and Closing of Underwriter’s Over-Allotment Option

    NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that the underwriter of its previously announced underwritten public offering has exercised, in full, its option to purchase an additional 292,018 shares of common stock at a price of $1.34 per share. Total gross proceeds to the Company from the offering, including the funds received from the

  • GlobeNewswire

    Journey Medical Corporation Announces Closing of Initial Public Offering

    SCOTTSDALE, Ariz., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, and a subsidiary of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced the closing of its initial public offering of common stock of 3,520,000 shares at a public offering price of $10.00 per shar

Advertisement
Advertisement